EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Oragenics's enterprise value is $3.33 Mil.
Oragenics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil. Therefore, Oragenics's EV-to-Revenue for today is .
The historical rank and industry rank for Oragenics's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Oragenics was 145.34. The lowest was -13.76. And the median was -7.77.
OGEN's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 6.76 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2025-05-10), Oragenics's stock price is $0.1686.
Oragenics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00. Therefore, Oragenics's PS Ratio for today is .
Oragenics EV-to-Revenue Historical Data
The historical data trend for Oragenics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Oragenics's EV-to-Revenue
For the Biotechnology subindustry, Oragenics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oragenics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oragenics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Oragenics's EV-to-Revenue falls into.
Oragenics's current Enterprise Value is $3.33 Mil.
Oragenics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oragenics's share price for today is $0.1686.
Oragenics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oragenics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Oragenics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OGEN has been successfully added to your 